Replimune Group (NASDAQ:REPL) Shares Gap Up – Still a Buy?

Replimune Group, Inc. (NASDAQ:REPL)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $13.26, but opened at $13.64. Replimune Group shares last traded at $14.15, with a volume of 561,791 shares changing hands.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. HC Wainwright reissued a “buy” rating and set a $17.00 price objective on shares of Replimune Group in a research report on Friday, November 22nd. Roth Mkm initiated coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price objective on the stock. JPMorgan Chase & Co. raised their price target on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. Finally, BMO Capital Markets raised their price target on shares of Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a report on Friday, November 22nd. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Replimune Group has an average rating of “Buy” and a consensus target price of $17.00.

Replimune Group Trading Down 2.3 %

The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The company’s fifty day simple moving average is $11.77 and its 200-day simple moving average is $9.89. The company has a market capitalization of $961.26 million, a P/E ratio of -4.61 and a beta of 1.19.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. Research analysts predict that Replimune Group, Inc. will post -2.99 earnings per share for the current year.

Insider Buying and Selling at Replimune Group

In other news, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now owns 109,885 shares in the company, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jacobs Levy Equity Management Inc. purchased a new position in shares of Replimune Group during the 1st quarter worth approximately $1,088,000. Price T Rowe Associates Inc. MD increased its position in shares of Replimune Group by 12.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after purchasing an additional 699,679 shares in the last quarter. LMR Partners LLP increased its position in Replimune Group by 145.8% during the third quarter. LMR Partners LLP now owns 82,479 shares of the company’s stock worth $904,000 after buying an additional 48,920 shares during the period. Millennium Management LLC raised its position in Replimune Group by 575.1% in the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after purchasing an additional 2,656,173 shares during the last quarter. Finally, Cubist Systematic Strategies LLC raised its holdings in shares of Replimune Group by 282.2% in the second quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock valued at $650,000 after buying an additional 53,313 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.